Skip to main content

Enhanced oral unavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes

Nee Ling, S.S., Magosso, E., Khan, N.A.K., Kah, H.Y., Barker, S.A. (2006) Enhanced oral unavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Development and Industrial Pharmacy, 32 (3). pp. 335-345. ISSN 0363-9045. (doi:10.1080/03639040500519102) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:78862)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.
Official URL
https://doi.org/10.1080/03639040500519102

Abstract

A liposome system was evaluated for oral delivery of a poorly bioavailable hydrophilic drug. The system was prepared from proliposome, which consisted of negatively charged phosphatidylcholine, whereas cefotaxime was chosen as the model drug. An in vivo study was carried out on nine rats according to a three-way crossover design to compare the oral bioavailability of cefotaxime from the liposomal formulation with that of an aqueous drug solution and a physical mixture of cefotaxime with blank liposomes. The results indicated that the extent of bioavailability of cefotaxime was increased approximately 2.7 and 2.3 times compared with that of the aqueous solution and the physical mixture, respectively. In a separate study, simultaneous determination of cefotaxime in intestinal lymph (collected from the mesenteric lymph duct) and in plasma (collected from the tail vein) revealed that its concentration was consistently higher in the lymph than in the plasma when administered via the liposomal formulation, whereas the reverse was observed with the aqueous solution. Thus, the results indicated that the liposomes system has the potential of increasing the oral bioavailability of poorly bioavailable hydrophilic drugs and also promote their lymphatic transport in the intestinal lymph.

Item Type: Article
DOI/Identification number: 10.1080/03639040500519102
Uncontrolled keywords: Cefotaxime, Hydrophilic drug, Liposomes, Lymphatic transport, Oral administration, cefotaxime, liposome, phosphatidylcholine, pro lipo duo, antiinfective agent, cefotaxime, liposome, phosphatidylcholine, adsorption kinetics, animal experiment, animal model, aqueous solution, article, comparative study, controlled study, crossover procedure, drug absorption, drug bioavailability, drug delivery system, drug formulation, drug transport, hydrophilicity, intestine absorption, lymphatic system, male, nonhuman, rat, animal, area under the curve, bioavailability, chemistry, lymphatic system, metabolism, particle size, Sprague Dawley rat, Animals, Anti-Bacterial Agents, Area Under Curve, Biological Availability, Cefotaxime, Cross-Over Studies, Liposomes, Lymphatic System, Male, Particle Size, Phosphatidylcholines, Rats, Rats, Sprague-Dawley
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User: Susan Barker
Date Deposited: 27 Nov 2019 12:39 UTC
Last Modified: 16 Nov 2021 10:26 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/78862 (The current URI for this page, for reference purposes)
Barker, S.A.: https://orcid.org/0000-0003-4880-0253
  • Depositors only (login required):